Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma
CONCLUSIONS: The early outcomes of pembrolizumab with chemotherapy in the neoadjuvant setting as a novel treatment for resectable stage IIB-IIIB LUSC showed a high pCR rate that has not been seen previously, as well as a high R0 resection rate and a low toxicity profile. The long-term efficacy of this novel treatment and the validity of the present findings should be confirmed with longer follow-up and prospective comparative trials.PMID:33841966 | PMC:PMC8024839 | DOI:10.21037/jtd-21-103
Source: Journal of Thoracic Disease - Category: Respiratory Medicine Authors: Dijian Shen Jiangfeng Wang Jie Wu Sheng Chen Jianqiang Li Jinshi Liu Qixun Chen Youhua Jiang Source Type: research
More News: Abraxane | Cancer | Cancer & Oncology | Carcinoma | Cardiovascular & Thoracic Surgery | Chemotherapy | CT Scan | Immunotherapy | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer | Respiratory Medicine | Skin Cancer | Squamous Cell Carcinoma | Study | Toxicology